Literature DB >> 19632957

Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults.

Leigh Anne Redhage1, Ayumi Shintani, David W Haas, Nkiruka Emeagwali, Milica Markovic, Ikwo Oboho, Christopher Mwenya, Husamettin Erdem, Edward P Acosta, Jason D Morrow, Todd Hulgan.   

Abstract

PURPOSE: Oxidant stress may be an effect of antiretroviral therapy (ART) or chronic HIV infection. Plasma F2-isoprostanes (F2-IsoP) reflect lipid peroxidation and oxidant stress and have been described in ART-associated toxicities. We explored factors associated with F2-IsoP in HIV-infected adults.
METHODS: HIV-infected adults enrolled in this cross-sectional study were (a) on ART including zidovudine or stavudine but not non-nucleoside reverse transcriptase inhibitors (NNRTI), (b) on ART including NNRTI, or (c) not on ART. Plasma F2-IsoP levels were quantified by GC/MS, and clinical and laboratory data were collected at enrollment.
RESULTS: Among 285 participants, 24% were female, 37% were African American, and 194 (68%) were on ART; 44 (23%) of whom were receiving efavirenz, 45 (23%) nevirapine, and 85 (44%) protease inhibitors. Median F2-IsoP was lower in those on NNRTI than those on ART without NNRTI (p = .02). In a multivariable model, factors independently associated with increased F2-IsoP were female sex (p = .002), higher BMI (p = .01), and heavy smoking (p = .004). There was a trend toward lower F2-IsoP among nevirapine users (p = .054).
CONCLUSIONS: Among HIV-infected adults, oxidant stress status differs by sex, BMI, smoking status, and perhaps specific ART. Prospective studies should better define relationships between oxidant stress and complications of HIV infection and its therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19632957      PMCID: PMC2891063          DOI: 10.1310/hct1003-181

Source DB:  PubMed          Journal:  HIV Clin Trials        ISSN: 1528-4336


  44 in total

Review 1.  The isoprostanes: unique bioactive products of lipid peroxidation.

Authors:  J D Morrow; L J Roberts
Journal:  Prog Lipid Res       Date:  1997-03       Impact factor: 16.195

2.  Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage.

Authors:  J D Morrow; B Frei; A W Longmire; J M Gaziano; S M Lynch; Y Shyr; W E Strauss; J A Oates; L J Roberts
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

3.  Plasma F2-isoprostanes and coronary artery calcification: the CARDIA Study.

Authors:  Myron Gross; Michael Steffes; David R Jacobs; Xinhua Yu; Linda Lewis; Cora E Lewis; Catherine M Loria
Journal:  Clin Chem       Date:  2004-10-28       Impact factor: 8.327

4.  Oxidant stress is increased during treatment of human immunodeficiency virus infection.

Authors:  Todd Hulgan; Jason Morrow; Richard T D'Aquila; Stephen Raffanti; Michael Morgan; Peter Rebeiro; David W Haas
Journal:  Clin Infect Dis       Date:  2003-11-19       Impact factor: 9.079

5.  Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection.

Authors:  Pablo Tebas; Kevin Yarasheski; Keith Henry; Sherri Claxton; E Kane; B Bordenave; Michael Klebert; William G Powderly
Journal:  AIDS Res Hum Retroviruses       Date:  2004-06       Impact factor: 2.205

Review 6.  Oxidative DNA damage: assessment of the role in carcinogenesis, atherosclerosis, and acquired immunodeficiency syndrome.

Authors:  Ryszard Olinski; Daniel Gackowski; Marek Foksinski; Rafal Rozalski; Krzysztof Roszkowski; Pawel Jaruga
Journal:  Free Radic Biol Med       Date:  2002-07-15       Impact factor: 7.376

7.  Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients.

Authors:  T A Ikizler; J D Morrow; L J Roberts; J A Evanson; B Becker; R M Hakim; Y Shyr; J Himmelfarb
Journal:  Clin Nephrol       Date:  2002-09       Impact factor: 0.975

8.  A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study.

Authors:  Cesar Fisac; Nuria Virgili; Elena Ferrer; Maria J Barbera; Emilio Fumero; Concepcio Vilarasau; Daniel Podzamczer
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

9.  Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors.

Authors:  J M Petit; M Duong; D Masson; M Buisson; L Duvillard; J B Bour; M C Brindisi; F Galland; M Guiguet; P Gambert; H Portier; B Vergès
Journal:  Eur J Clin Invest       Date:  2004-08       Impact factor: 4.686

Review 10.  Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases.

Authors:  Kathleen S Montine; Joseph F Quinn; Jing Zhang; Joshua P Fessel; L Jackson Roberts; Jason D Morrow; Thomas J Montine
Journal:  Chem Phys Lipids       Date:  2004-03       Impact factor: 3.329

View more
  14 in total

1.  A randomized, controlled trial of the effect of rilpivirine versus efavirenz on cardiovascular risk in healthy volunteers.

Authors:  Samir K Gupta; James E Slaven; Lisa M Kamendulis; Ziyue Liu
Journal:  J Antimicrob Chemother       Date:  2015-07-13       Impact factor: 5.790

2.  Sex differences in urinary biomarkers of vascular and endothelial function in HIV-infected persons receiving antiretroviral therapy.

Authors:  Michael S Boger; Aihua Bian; Ayumi Shintani; Ginger L Milne; Jason D Morrow; Husamettin Erdem; Valerie Mitchell; David W Haas; Todd Hulgan
Journal:  Antivir Ther       Date:  2011-12-14

Review 3.  The isoprostanes--25 years later.

Authors:  Ginger L Milne; Qi Dai; L Jackson Roberts
Journal:  Biochim Biophys Acta       Date:  2014-10-30

Review 4.  Isoprostane generation and function.

Authors:  Ginger L Milne; Huiyong Yin; Klarissa D Hardy; Sean S Davies; L Jackson Roberts
Journal:  Chem Rev       Date:  2011-08-18       Impact factor: 60.622

5.  Higher serum iron is associated with increased oxidant stress in HIV-infected men.

Authors:  Matthew B Crist; Vlada V Melekhin; Aihua Bian; Ayumi Shintani; Ginger L Milne; Asha R Kallianpur; Leigh A Dageforde; David W Haas; Todd Hulgan
Journal:  J Acquir Immune Defic Syndr       Date:  2013-12-01       Impact factor: 3.731

6.  Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study.

Authors:  Samir K Gupta; Changyu Shen; Sharon M Moe; Lisa M Kamendulis; Mitchell Goldman; Michael P Dubé
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

7.  Urine Eicosanoids in the Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial.

Authors:  Catherine N Le; Todd Hulgan; Chi-Hong Tseng; Ginger L Milne; Jordan E Lake
Journal:  PLoS One       Date:  2017-01-24       Impact factor: 3.240

8.  HIV infection, antiretroviral therapy, and measures of endothelial function, inflammation, metabolism, and oxidative stress.

Authors:  Andrew Dysangco; Ziyue Liu; James H Stein; Michael P Dubé; Samir K Gupta
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.240

9.  Antiretroviral Therapy Initiation Alters the Redox System of Asymptomatic HIV-Infected Individuals: A Longitudinal Study.

Authors:  Karen Ingrid Tasca; Juliana Trindade Caleffi; Camila Renata Correa; Mariana Gatto; Francilene Capel Tavares; Caio Cavassan Camargo; Alexandrina Sartori; Mara Biasin; Lenice do Rosário de Souza
Journal:  Oxid Med Cell Longev       Date:  2017-03-21       Impact factor: 6.543

10.  Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial.

Authors:  Todd Hulgan; M Sean Boger; Diana H Liao; Grace A McComsey; Christine A Wanke; Alexandra Mangili; Sharon L Walmsley; Heather McCreath; Ginger L Milne; Stephanie C Sanchez; Judith S Currier; Jordan E Lake
Journal:  Mediators Inflamm       Date:  2014-06-01       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.